Vinay Prasad Reinstated at FDA’s CBER After Abrupt Departure

Vinay Prasad has been reinstated as the director of the Center for Biologics Evaluation and Research (CBER) at the FDA, just weeks after his unexpected departure amid political controversy. The U.S. Department of Health and Human Services confirmed his return at the FDA’s request, following pleas from agency leadership. Prasad’s reappointment comes amid ongoing debates over vaccine regulation and federal research policy, signaling a notable leadership restoration at CBER.